Internet of Medical Things [IoMT] Market Size & Industry Analysis 2034

0
2K

The Global Internet of Medical Things [IoMT] Market has witnessed continuous growth in the last few years and is projected to grow even further during the forecast period of 2024-2033. The assessment provides a 360° view and insights - outlining the key outcomes of the Internet of Medical Things [IoMT] market, current scenario analysis that highlights slowdown aims to provide unique strategies and solutions following and benchmarking key players strategies. In addition, the study helps with competition insights of emerging players in understanding the companies more precisely to make better informed decisions.

Browse for Full Report at @ https://www.thebrainyinsights.com/report/internet-of-medical-things-iomt-market-13410


Reference — companies (with headline values / notes)

  • Philips (Philips Healthcare) — major connected devices & remote monitoring platforms (hospital and home-health lines). Philips 2024 reported group revenue ≈ €18–19B (healthcare a large share). 

  • GE HealthCare — broad device portfolio (imaging + monitoring) and software/cloud services for device connectivity; GE HealthCare FY2024 revenue ≈ $18–19B

  • Medtronic — connected implantables and hospital-connected therapeutic devices; FY2024/2025 revenue ~$33–34B (large medtech anchor).Siemens Healthineers — imaging + clinical IT + device connectivity; FY2024 revenue ~€22–24B

  •  
  • Abbott / Boston Scientific / Dexcom / Baxter / Biofourmis / Cisco / IBM — each appears frequently in IoMT reports: Abbott & Dexcom (wearables/CGM), Boston Scientific (connected implants), Biofourmis (RPM/AI), Cisco/IBM (connectivity, cybersecurity & cloud). 

(If you’d like a downloadable table with exact FY2023–24 revenues + brief IoMT product notes for the top 12 vendors, I can build that next.)


Market size — representative published estimates (pick scope carefully)

  • Grand View Research: global IoMT market USD 230.69 billion (2024); CAGR ~18.2% (2025–2030).

  • Mordor Intelligence: USD 56.07 billion (2025) → USD 125.49 billion (2030); CAGR ~17.5%. 

  • Fortune Business Insights: a much larger projection (scope-dependent): USD 60.03B (2024) → USD 814.28B by 2032 (CAGR 38.5%) (note: this estimate uses a very broad, expansive scope).

  • ResearchAndMarkets / GlobeNewswire also publish mid-range forecasts (e.g., ~USD 97–245B depending on year/scope).

Takeaway: expect mid-to-high double-digit CAGRs in most vendor reports; choose the forecast aligned to the device + services scope you care about (wearables + RPM vs. full device + IT + services).


Recent developments (2023–mid-2025)

  • Remote Patient Monitoring (RPM) commercialization & reimbursement momentum — more FDA-cleared algorithms and platforms, and stronger provider adoption of RPM programs. Biofourmis and others obtained clinical/algorithm clearances and RPM became central to many care pathways.

  • Acceleration of connected consumer health devices (CGMs, wearables, smart rings) feeding clinical pipelines (Dexcom, Abbott, Oura, etc.). CGM growth and consumer health trends have broadened IoMT use-cases.

  • Increased attention to device cybersecurity & interoperability after publicized incidents and scale of device networks—health systems are investing in security for networked clinical assets. 


Drivers

  • Aging populations & chronic disease load (need for continuous monitoring and home-based care). 

  • Reimbursement & health-system adoption of RPM / telehealth (policy backing drives commercial uptake). 

  • Advances in sensors, low-power wireless (BLE, NB-IoT, 5G) and cloud analytics that make connected devices practical at scale.


Restraints

  • Fragmented regulation & lengthy clinical validation / approvals across jurisdictions (device + software/AI approvals). 

  • Cybersecurity & patient-data privacy risk — major barrier for hospital-scale rollouts.

  • Integration & workflow friction — EHR interoperability and clinician workflow disruption slow adoption.


Regional segmentation (high level)

  • North America — early adopter & largest share in many reports (strong RPM reimbursement moves and high device adoption).

  • Europe — strong hospital deployments and regulated adoption; privacy/regulatory constraints shape product design.

  • Asia-Pacific — fastest volume growth (wearables, mobile health, large patient pools in China/India; aggressive digital health investments).


Emerging trends

  • Clinical-grade consumer wearables & sensors blurring lines between consumer health and regulated medical devices (CGMs, smart rings, implanted sensors). 

  • AI/edge analytics embedded in devices (on-device inference + cloud models) to reduce latency and bandwidth needs.

  • Platformification: device vendors partnering with EHR/cloud players (Cisco/IBM/Philips) to offer end-to-end solutions (device management, security, analytics). 


Top use cases

  • Remote patient monitoring (chronic disease — HF, COPD, diabetes) and post-acute/home recovery monitoring.

  • In-hospital device connectivity & asset monitoring (ventilators, infusion pumps, telemetry).

  • Clinical trials & decentralized trials (digital biomarkers & continuous monitoring)


Major challenges

  • Security incidents & liability — device/network breaches can halt deployments. 

  • Evidence & clinical validation — payors and providers demand outcomes data demonstrating clinical and economic benefit.

  • Complex ecosystem & fragmented standards (many device types, networks, vendors) → integration overhead.


Attractive opportunities

  • Value-based care & RPM services — vendors that combine devices + analytics + care pathways (Biofourmis-style models) can capture higher-margin recurring revenue. 

  • Clinical-grade consumer device OEMs entering medical markets (CGM, smart ring vendors) — new addressable markets.

  • Security + device-management platforms (Cisco, IBM, Philips) — hospitals will pay for hardened, managed IoMT infrastructure.


Key factors of market expansion

  1. Reimbursement & regulatory clarity for RPM and software-as-medical-device (SaMD). 

  2. Robust clinical evidence proving outcome & cost benefits (drives hospital & payor adoption).

  3. Interoperability (standards + EHR integrations) and secure connectivity to enable safe scaling.

  4. Sensor & battery improvements + low-cost connectivity (NB-IoT/5G) reducing device TCO.


If you want next

Pick one and I’ll build it now (I’ll generate it immediately):

  1. Company table — top 12 IoMT companies with FY2023–24 revenues + 1-line IoMT product note.

  2. 1-page slide — market size range (3 forecasts), top vendors, 3 near-term risks to watch.

  3. Short investor memo (1 page) focused on RPM — size, regulatory timeline, 3 investment theses.

Which would you like?

Cerca
Categorie
Leggi tutto
Shopping
De ultieme gids voor haarwax: de beste soorten, toepassingen en stylingtips voor mannen
Haarwax is een van de meest veelzijdige en effectieve stylingproducten voor mannen, geschikt voor...
By Haar Palneet 2025-11-19 07:06:18 0 4K
Altre informazioni
What Services Should You Expect from the Best SEM Agency in Dubai?
In today’s digital-first business environment, having a website is just the beginning. To...
By Pluspoint Digital 2026-03-23 13:54:33 0 1K
Altre informazioni
PP Jumbo Bags for Agriculture and Industrial Applications
PP Jumbo bags are designed for bulk jobs, and that is precisely why they enjoy great popularity....
By Mahira Polyglobal Llp 2026-06-24 13:41:42 0 280
Altre informazioni
Catalyst Market Size, Share, Trends, Demand, Growth, Challenges and Competitive Outlook
"Executive Summary: Catalyst Market Size and Share by Application & Industry Data...
By Nshita Hande 2025-08-19 09:55:28 0 2K
Networking
Why Does the North America Prostate Cancer Diagnostics Market Lead in Innovation?
Comprehensive Outlook on Executive Summary North America Prostate Cancer Diagnostics...
By Ksh Dbmr 2025-12-26 06:10:27 0 2K
JogaJog https://jogajog.com.bd